Use of new, once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis. Is there anything new under the sun? [PDF]
, 2009 5-aminosalicylate (5-ASA) agents remain the mainstay treatment in ulcerative colitis (UC). A number of oral 5-ASA agents are commercially available, including azobond pro-drugs, as well as delayed- and controlled-release forms of mesalazine.
Lakatos, Péter László
core +2 more sources
Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer
Molecular Oncology, EarlyView.G protein‐coupled receptor 4 (GPR4) is a pH‐sensing receptor activated by acidic pH. GPR4 expression is increased in patients with inflammatory bowel disease who are at high risk of developing colorectal cancer. In mouse models, loss of GPR4 attenuated tumor progression. This correlated with increased IL2 and natural killer cell activity.
Leonie Perren +16 more
wiley +1 more source
Helminths in the gastrointestinal tract 1 as modulators of immunity and pathology [PDF]
, 2017 Helminth parasites are highly prevalent in many low- and middle-income countries, in which inflammatory bowel disease and other immunopathologies are less frequent than in the developed world.
Fleming, John O. +2 more
core +1 more source
Arthritis Care &Research, EarlyView.Objective Targeted synthetic disease‐modifying antirheumatic drugs (tsDMARDs) have expanded the management of autoimmune diseases, including rheumatic diseases. As the use of these drugs grows, it is important to understand their effects on pregnancy.
Vienna Cheng +7 more
wiley +1 more source
Identification of biomarkers of colitis to monitor effects of dietary omega-3 polyunsaturated fatty acids in the interleukin-10 gene-deficient mouse model of inflammatory bowel diseases : a thesis presented in partial fulfilment of the requirements for the degree of Doctor of Philosophy in Nutritional Science at Massey University, Manawatū, New Zealand [PDF]
, 2016 Inflammatory bowel diseases (IBD) are characterised by chronic inflammation of the gastrointestinal tract including the colon (colitis). Increased dietary intake of salmon, which is rich in eicosapentaenoic acid (EPA), was well tolerated by IBD patients,
Berger, Nadja
core
The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice. [PDF]
, 2013 The specific inhibition of phosphodiesterase (PDE)4 and dual inhibition of PDE3 and PDE4 has been shown to decrease inflammation by suppression of pro-inflammatory cytokine synthesis.
A Hatzelmann +43 more
core +4 more sources
Advanced Healthcare Materials, EarlyView.Schematic illustration of the mechanism of targeted delivery of nanoparticles including 1) paracellular, 2) endolysosomal escape, 3) receptor mediated endocytosis, and 4) M cell mediated transport for non‐GI diseases by oral administration such as atherosclerosis, cancer, diabetes, and brain diseases. Abstract Oral drug delivery is a promising approach
Subarna Ray +2 more
wiley +1 more source
Surgery and Ulcerative Colitis [PDF]
, 2002 The management of ulcerative colitis requires the collaboration of various teams looking after the patient and any decision regarding surgery should involve not only the patient and the surgeons but also various other professionals looking after the ...
Debono, Joseph, Gatt, Dennis
core
Advanced Healthcare Materials, EarlyView.Deinococcus radiodurans‐derived extracellular vesicles (R1‐EVs) provide radioprotection against total‐body irradiation‐induced acute radiation syndrome in mice. R1‐EVs mitigate oxidative damage by scavenging free radicals, promoting intestinal repair, enhancing hematopoietic function, and modulating immune responses. This study highlights the potential
Jeong Moo Han +7 more
wiley +1 more source
Anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease and their first-degree relatives: Potential clinical value [PDF]
, 2002 Anti-Saccharomyces cerevisiae antibodies (ASCA) have been described as specific markers in Crohn's disease and their healthy first-degree relatives. 171 patients with Crohn's disease, their 105 first-degree relatives, 145 patients with ulcerative colitis
Folwaczny, Christian +5 more
core +1 more source